ann: data from final cohort of patients, page-27

I think this is going to force hands here between parties -


Look at Dr. Leo Rasche's paper - “A monoclonal IgM antibody with specificity to heat shock protein GRP78/BIP shows anti-myeloma activity in vitro and in vivo, synergy in combination with Lenalidomide and safety in a pilot Phase I study”.

Look at what has been shown with Lenalidomide (Revlimid) & now Amgen/Onyx move in combination with Kyprolis although it still doesn't imply it to be locked down with SM6 it's just funding the trial to see.

So who wants what more - Amgen or Celgene ? and is there an impetus ?

I think someone has to move soon.